Scientific Advisory Board
Pamela M. Klein, B.Sc., M.D.
Dr. Pamela M. Klein completed her medical training at Stritch School of Medicine, Loyola University in Chicago, followed by internal medicine training at Cedars-Sinai, Los Angeles, prior to spending 7 years working at the U.S. National Cancer Institute. Dr. Klein then moved to Genentech where, as Vice President, Development she led the development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds. After Genentech Dr. Klein was appointed to the position of Chief Medical Officer of Intellikine where she built the clinical development capability and brought multiple early compounds from laboratory to clinic prior to Intellikine before being acquired by Millennium/Takeda. Currently, Dr. Klein currently serves as an advisor to a range of different biotech and investment companies, with roles on Scientific Advisory Boards and Corporate Boards as well as broader advisory roles.
Allen Ebens, B.Sc., Ph.D.
Dr. Allen Ebens completed a PhD at UCLA and Post-doctoral training at UCSF before joining Exelixis as a scientist in the Discovery Biology group. After 6 years with Exelixis Dr. Ebens moved to Genentech where he worked in Research Oncology for 11 years developing therapeutics from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, and antibody-drug conjugates. Dr. Ebens was recruited from Genentech to establish Research Oncology at Juno Therapeutics, and has served more recently as Senior Director of Immune Oncology at NGM Biopharmaceuticals. Dr. Ebens is currently Chief Scientific Officer of Trucode Gene Repair. Over a twenty year career Dr. Ebens’ contributions include significant contributions to the scientific literature as well as advancement of five discovery projects to clinical development.